Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.2970 -0.0030 (-1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch
Via AB Newswire
Topics Artificial Intelligence
These stocks are making the most noise in today's session. ↗
Via Chartmill
MissionIRNewsBreaks – SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics
Via Investor Brand Network
News headline image
Vistagen Appoints Douglas J. Williamson to its Board of Directors
Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy 
From Vistagen Therapeutics, Inc.
Via GlobeNewswire
Vistagen Therapeutics (NASDAQ:VTGN) Faces Muted Market Sentiment as Crucial PALISADE-4 Data Looms ↗
Via Chartmill
Unusual volume stocks in Thursday's session ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Vistagen
Via Business Wire
News headline image
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
From Vistagen
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
VTGN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.